Clinical Trial Update: A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 biomarker study evaluating the combination of palbociclib and fulvestrant in second- or third-line HR+/HER2-negative advanced breast cancer in postmenop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Breast Cancer, HR+/HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN